Cargando…
Updates on cardiovascular outcome trials in diabetes
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular...
Autores principales: | Schnell, Oliver, Rydén, Lars, Standl, Eberhard, Ceriello, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637292/ https://www.ncbi.nlm.nih.gov/pubmed/29020969 http://dx.doi.org/10.1186/s12933-017-0610-y |
Ejemplares similares
-
Correction to: Updates on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2017) -
Current perspectives on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2016) -
Type 1 diabetes and cardiovascular disease
por: Schnell, Oliver, et al.
Publicado: (2013) -
Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
por: Schnell, Oliver, et al.
Publicado: (2020) -
Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2016)